Patent Application: Tumor Targeting Methods and Reagents
Summary
The USPTO has published a patent application (US20260083867A1) detailing methods and reagents for tumor targeting in cancer treatment. The application, filed on November 21, 2025, describes a combination therapeutic approach using agents with different biodistributions to enhance efficacy and reduce toxicity.
What changed
This document is a published patent application from the USPTO for a novel method and reagents for tumor targeting in cancer treatment. The invention involves administering two agents, each with a targeting component coupled to a therapeutic component, where the targeting components have distinct biodistributions or pharmacokinetics. This approach aims to improve treatment efficacy and reduce toxicity.
While patent applications do not impose direct regulatory obligations on companies, they signal potential future intellectual property and market exclusivity in specific therapeutic areas. Companies involved in oncology drug development, particularly those exploring combination therapies or novel targeting mechanisms, should be aware of this filing. It may influence R&D strategies and competitive landscapes in the pharmaceutical sector.
Archived snapshot
Mar 26, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
METHODS AND REAGENTS FOR TUMOR TARGETING WITH GREATER EFFICACY AND LESS TOXICITY
Application US20260083867A1 Kind: A1 Mar 26, 2026
Inventors
Neil H. BANDER
Abstract
The present invention relates to a method for treating cancer. This method involves providing a first agent comprising a first targeting component coupled to a first cancer therapeutic component and providing a second agent comprising a second targeting component coupled to a second cancer therapeutic component. The first and second targeting components have different biodistributions and/or pharmacokinetics. The first and second agents are administered to a subject having cancer to treat the cancer. Also disclosed is a combination therapeutic comprising the first and second agents.
CPC Classifications
A61K 51/1072 A61K 51/0402 A61P 35/00
Filing Date
2025-11-21
Application No.
19396767
Named provisions
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.